Literature DB >> 31380732

Technology preferences to enhance HIV and HCV care among patients with substance use disorders.

Babak Tofighi1,2,3, Paul Hein1, Alexandre M S Carvalho4, Joshua D Lee1,2,3, Noelle R Leonard3,5.   

Abstract

We examined technology use patterns (e.g., mobile phone and computer ownership, text messaging, internet access) and preferences for adopting health information technologies to optimize office-based treatment for substance use disorders, HIV, and Hepatitis C virus (HCV) infection. Surveys were administered to patients enrolled in inpatient detoxification program in a publicly-funded tertiary referral center. Most reported mobile phone ownership (86%) and described high rates of mobile phone (3.3) and phone number (2.6) turnover in the preceding year. Internet access was reported on a daily (52%) or weekly basis (22%). Most participants were amenable to receiving text message-based informational content (i.e., medications, support groups, treatment programs) pertaining to substance use disorders (79%), HIV (50%), and HCV care (58%). Respondents reporting less than high school education and past year incarcerated elicited higher favorability in adopting smartphone apps to facilitate peer sharing of HIV-HCV related content. Results suggest high favorability for adopting health information technologies to enhance office-based treatment for substance use disorders, HIV, and HCV, particularly among vulnerable patient sub-groups.

Entities:  

Keywords:  HIV; Hepatitis C; Opioid use disorder; mobile health; technology based intervention

Year:  2019        PMID: 31380732      PMCID: PMC6946844          DOI: 10.1080/10550887.2019.1640056

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  1 in total

1.  Mobile phone ownership, digital technology use and acceptability of digital interventions among individuals on opioid use disorder treatment in Kenya.

Authors:  Sarah Kanana Kiburi; Saeeda Paruk; Bonginkosi Chiliza
Journal:  Front Digit Health       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.